Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ripply transcriptional repressor 2 (RIPPLY2) is a nuclear protein and member of the Ripply family involved in vertebrate somitogenesis and segmentation of the axial skeleton. RIPPLY2 contains a WRPW tetrapeptide motif, essential for interaction with the transcriptional co-repressor Groucho, and a C-terminal homology domain critical for its function. RIPPLY2 modulates transcription of T-box family transcription factors, such as Tbx6, often by recruiting the 26S proteasome complex to degrade these proteins in a highly tissue- and context-specific manner, especially in presomitic mesoderm (PSM) cells. Mutations or loss of RIPPLY2 disrupt normal somite formation and patterning, leading to conditions such as spondylocostal dysostosis. Though mechanistically important in embryogenesis, RIPPLY2 is not currently recognized as a clinical drug target, nor is it associated with known pharmacological agents, mechanisms, or safety concerns in a therapeutic setting
Not applicable. No drugs known to target RIPPLY2
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ripply transcriptional repressor 2 (RIPPLY2).